- Open Access
Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice
© Paddenberg et al. 2007
Received: 02 November 2006
Accepted: 24 February 2007
Published: 24 February 2007
Chronic hypoxia induces pulmonary arterial hypertension (PAH). Smooth muscle cell (SMC) proliferation and hypertrophy are important contributors to the remodeling that occurs in chronic hypoxic pulmonary vasculature. We hypothesized that rapamycin (RAPA), a potent cell cycle inhibitor, prevents pulmonary hypertension in chronic hypoxic mice.
Mice were held either at normoxia (N; 21% O2) or at hypobaric hypoxia (H; 0.5 atm; ~10% O2). RAPA-treated animals (3 mg/kg*d, i.p.) were compared to animals injected with vehicle alone. Proliferative activity within the pulmonary arteries was quantified by staining for Ki67 (positive nuclei/vessel) and media area was quantified by computer-aided planimetry after immune-labeling for α-smooth muscle actin (pixel/vessel). The ratio of right ventricle to left ventricle plus septum (RV/[LV+S]) was used to determine right ventricular hypertrophy.
Proliferative activity increased by 34% at day 4 in mice held under H (median: 0.38) compared to N (median: 0.28, p = 0.028) which was completely blocked by RAPA (median HO+RAPA: 0.23, p = 0.003). H-induced proliferation had leveled off within 3 weeks. At this time point media area had, however, increased by 53% from 91 (N) to 139 (H, p < 0.001) which was prevented by RAPA (H+RAPA: 102; p < 0.001). RV/[LV+S] ratio which had risen from 0.17 (N) to 0.26 (H, p < 0.001) was attenuated in the H+RAPA group (0.22, p = 0.041). For a therapeutic approach animals were exposed to H for 21 days followed by 21 days in H ± RAPA. Forty two days of H resulted in a media area of 129 (N: 83) which was significantly attenuated in RAPA-treated mice (H+RAPA: 92). RV/[LV+S] ratios supported prevention of PH (N 0.13; H 0.27; H+RAPA 0.17). RAPA treatment of N mice did not influence any parameter examined.
Therapy with rapamycin may represent a new strategy for the treatment of pulmonary hypertension.
Pulmonary arterial hypertension (PAH), a disease of the small pulmonary arteries, is characterized by vascular proliferation and remodeling . It results in a progressive increase in pulmonary vascular resistance and, ultimately, right ventricular failure and death. One trigger of PAH is hypoxia which acutely causes a rise in pulmonary blood pressure by vasoconstriction but chronically results in the structural remodeling of the pulmonary vasculature . Medial thickening of small pulmonary arteries has long been recognized as one of the earliest pathologic features, indicating proliferation of smooth muscle cells (SMC) . Indeed, smooth muscle cell proliferation in small, peripheral, normally nonmuscular pulmonary arterioles is a hallmark of PAH [4, 5].
The current medical management of PAH is directed at vasodilatation rather than towards inhibition of smooth muscle cell proliferation . However, recently an exciting new therapeutic avenue has been taken using a platelet-derived growth factor (PDGF) receptor antagonist to treat PAH in hypoxic rats . This approach has even successfully been used in a single patient with end stage primary pulmonary hypertension . Anti-proliferative therapy seems to offer a novel approach for treatment of PAH.
Rapamycin (sirolimus) is another very potent anti-proliferative drug. Through inhibition of its target, the mammalian Target of Rapamycin (mTOR), rapamycin blocks mitogen-induced signaling via phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt) towards the cell cycle machinery in SMC in vitro and in vivo . In cardiovascular medicine, rapamycin is successfully used as stent-coating for prevention of in-stent restenosis [9–11]. However, rapamycin also abrogates hypoxia-induced increase in proliferation of cultured smooth muscle and endothelial cells . Furthermore, the requirement of PI3K, Akt, and mTOR in hypoxia-induced pulmonary artery adventitial fibroblast proliferation has been demonstrated recently .
On this background we hypothesized that rapamycin prevents and reverses hypoxia-induced vascular remodeling. Mice were injected with rapamycin or with vehicle alone (0.2% carboxymethylcellulose) and held either at normoxia (21% O2) or at hypobaric hypoxia (0.5 atm; ~10% O2). Frozen lung sections of mice kept for four days or three weeks at normoxia or hypobaric hypoxia were employed for double labeling for Ki67 (proliferating cells) and α-smooth muscle actin to quantify the proliferative activity of the pulmonary vasculature and to determine the vessel media area by computer-aided planimetry. In hematoxylin-eosin stained cross sections of frozen hearts, calculation of the ratio of the areas of right ventricular wall/[left ventricular wall + septum] and measurement of the diameters of individual cardiomyocytes served for the estimation of right ventricular hypertrophy. Our results demonstrated that rapamycin is able to attenuate hypoxia-induced proliferation and thickening of the pulmonary vasculature as well as right ventricular hypertrophy thereby supporting that anti-proliferative regimens offer a novel approach for anti-remodeling therapy in hypoxia-induced PAH.
Chemicals and antibodies
Rapamycin was a kind gift from Wyeth Pharmaceuticals (Muenster, Germany). FITC-conjugated monoclonal anti-α-smooth muscle actin antibody (clone 1A4) and 4',6-diamidino-2-phenyl-inodole (DAPI) were obtained from Sigma-Aldrich (Deisenhofen, Germany), rabbit polyclonal anti-Ki67 antibody from Novocastra Laboratories Ltd. (Dossenheim, Germany) and Cy3-conjugated donkey anti-rabbit antibody from Dianova (Hamburg, Germany).
Animals and experimental protocol
FVB mice of both gender were obtained from Harlan Winkelmann (Paderborn, Germany) and used at 6–8 weeks of age. The animals were fed standard mouse chow and were allowed to take food and water ad libidum. All experiments conformed to the NIH guidelines to the care and use of experimental animals, and were approved by the local authorities.
The kinetic of proliferation within the walls of intrapulmonary vessels in response to reduced oxygen supply was examined in mice kept for 2, 3, 4, 10, 16, or 21 days in a hypobaric chamber. An air intake valve was adjusted to maintain intrachamber pressure at 380 mmHg (0.5 atm) while allowing adequate airflow through the chamber to prevent accumulation of CO2 and NH3. Control mice were kept at normobaric pressure (760 mmHg) at room air.
To examine the effect of rapamycin on hypoxia-induced vascular remodeling and right ventricular hypertrophy, age-matched mice were divided into 6 experimental groups: 1. untreated normoxic mice, 2. vehicle-treated normoxic mice, 3. rapamycin-treated normoxic mice, 4. untreated hypobaric mice, 5. vehicle-treated hypobaric mice, and 6. rapamycin-treated hypobaric mice. In some experiments solely four groups (vehicle-/rapamycin-treated mice at normoxia/hypoxia) were formed. For application of rapamycin or vehicle, the chamber was opened daily and the mice were weighed. An 1.75 mg/ml stock solution of rapamycin was freshly prepared every second day by homogenization of the drug in 0.2% carboxymethylcellulose as vehicle. Rapamycin was injected i.p. at 3 mg/kg*d in a final volume of 100 μl. Control mice received either the same volume of the vehicle or remained untreated.
Mice were sacrificed by cervical dislocation and exsanguinated by cutting the vena cava inferior. The chest cavity was opened, and the lungs were filled via the trachea with Zamboni fixative (2% formaldehyde, 15% saturated picric acid in 0.1 mol/L phosphate buffer). Heart and lungs were removed en block and transferred into Zamboni fixative. After fixation for 6 h, the tissue was washed overnight with 0.1 mol/L phosphate buffer and incubated for 3 days with increasing concentrations of sucrose solution (9%, 18% and 40% sucrose in 0.1 mol/L phosphate buffer). Finally, the specimens were embedded in optimal cutting temperature (OCT) compound (Sakura; Zoeterwoude, The Netherlands) and frozen in liquid nitrogen.
Immunohistochemical double-labeling of lung tissue for Ki67 (proliferating cells) and α-smooth muscle actin (vascular muscularization) was employed for a quantitative analysis of the proliferative activity of the pulmonary vasculature. For that purpose, 10 μm thick frozen sections were prepared and Ki67 antigen was unmasked by microwave treatment (twice for 6 min at 800 W in 0.1 mol/L sodium citrate buffer, pH 6.0). After blocking of unspecific protein binding sites, the frozen sections were incubated overnight simultaneously with FITC-conjugated anti-α-smooth muscle actin antibody and anti-Ki67 antibody (1:500 and 1:1000, respectively, in 5% bovine serum albumin, 5% normal goat serum in phosphate buffered saline (PBS)) followed by Cy3-conjugated donkey anti-rabbit antibody (1:2000 in 5% bovine serum albumin, 5% normal goat serum in PBS, 1 h at room temperature). After three washes with PBS the sections were incubated with 1 μg/ml DAPI in PBS for 15 min followed by three washes with PBS. Sections were evaluated with an epifluorescence microscope (BX60; Olympus, Hamburg, Germany) equipped with appropriate filter combinations. The number of cells with Ki67 positive nuclei detectable per cross section of a vessel was defined as "Ki67 positive cells/vessel". Per condition, two lung sections were analyzed, and the mean was calculated. The obtained data were statistically analyzed as described in "Statistical analysis".
The lung sections stained for α-smooth muscle actin were also used to evaluate by computer-aided planimetry the extent of muscularization of intrapulmonary vessels. For a quantitative analysis, the ratio of the number of α-smooth muscle actin positive pixels within a vessel wall and the minimal vascular diameter [μm] was calculated. Per condition about 100 vessels were analyzed and the median was calculated. The obtained data were statistically analyzed as described in "Statistical analysis".
Assessment of right ventricular hypertrophy
Right ventricular hypertrophy was investigated employing 10 μm thick frozen sections. In detail, cross sections of the heart embracing the walls of both ventricle and the septum were prepared and routinely stained with hematoxylin-eosin, dehydrated, and embedded in Entellan (Merck, Darmstadt, Germany). Heart sections were evaluated with a BX60 microscope (Olympus, Hamburg, Germany) employing Scion VisiCapture 1.0 software (Scion Coorporation, Frederick, Maryland, USA). The ratio of right ventricular wall area to left ventricular wall area plus septum area [RV/LV+S] was used as an index of right ventricular hypertrophy. To analyze the size of individual cardiomyocytes in cross sections of the right and left ventricle wall the diameter of individual myocytes was measured using an Axioplan 2 microscope (Zeiss, Jena, Germany) and employing the AxioVision 3.0 software (Zeiss, Jena, Germany).
Statistical analysis was performed by using SPSS Base 8.0 (SPSS Software, Munich, Germany). Percentiles 0, 25, 50, 75 and 100 are presented in box plots. Differences among experimental groups were analyzed with the Kruskal-Wallis and the Mann-Whitney tests, with p ≤ 0.05 being considered significant and p ≤ 0.01 highly significant.
Rapamycin prevents hypoxia-induced increase of proliferative activity within the pulmonary vasculature
Since proliferative activity had subsided after 3 weeks of exposure to hypoxia (Fig. 1), no effect of rapamycin was detectable after this time period (data not shown).
Rapamycin blocks the hypoxia-triggered media thickening of intrapulmonary vessels
In lung sections of mice kept for 4 days at hypobaric hypoxia a trend towards a thickened muscle layer compared to normoxic controls was already detectable. However, this difference was not significant (data not shown).
Three weeks of hypoxia, however, induced a distinct increase in muscularization of intrapulmonary vessels. The extent of muscularization rose about 53% both in untreated and vehicle-injected mice (in both cases p < 0.001) (Fig. 2B). Whereas under normoxic conditions the degree of muscularization was unchanged by rapamycin administration, in lungs of hypoxic mice a 26% reduction of the muscularization was detectable. The rapamycin-treated group did not differ significantly from animals housed at normoxia.
Hypoxia-induced right ventricular wall thickening is attenuated by rapamycin
Hypoxia-triggered hypertrophy of individual cardiomyocytes is reduced by rapamycin
Untreated or vehicle-treated mice kept at hypobaric hypoxia for 3 weeks exhibited a 20% increase in cardiomyocyte diameter compared to the normoxic reference groups (p < 0.001 in both cases). Whereas rapamycin had no effect on cardiomyocyte size of mice housed at normoxia, in hypoxic animals the diameter was significantly reduced (Fig. 4B).
Cardiomyocytes of the left ventricular wall exhibited distinctly larger diameters than those of the right ventricular wall. The size of the cells was affected neither by exposure to hypobaric hypoxia nor by application of rapamycin.
Rapamycin reverses hypoxia-induced pulmonary vascular remodeling
A therapeutic approach was probed: Mice were first exposed to hypobaric hypoxia for 3 weeks followed by another 3 weeks of hypoxia but daily rapamycin treatment. Age-matched controls were held at normoxia and treated for 3 weeks either with vehicle or with rapamycin.
In comparison to normoxia, hypoxia had again induced a shift of the relative proportion of arteries with diameters smaller than 20 μm. This shift was not affected by rapamycin treatment of the mice (data not shown).
The current medical management of PAH is directed at vasodilatation rather than towards inhibition of smooth muscle cell proliferation, although progression of pulmonary hypertension is known to be associated with increased proliferation . However, the data of this experimental study imply that targeting vascular remodeling processes may represent a promising therapeutic approach towards hypoxia-induced PAH, too.
This exciting avenue has very recently been gone by Schermuly et al. demonstrating a reversal of pulmonary remodeling processes in hypoxia-induced PAH by the platelet-derived growth factor (PDGF) receptor antagonist imatinib mesylate . In a case report of a patient in a desperate situation of progressing pulmonary hypertension, Seeger's group further substantiates this new concept . PDGF represents a potent mitogen for pulmonary smooth muscle cells  acting via PI3K/Akt/mTOR, a central signaling pathway for cell cycle entry and progression. This pathway is activated by other growth factors involved in PAH as well  suggesting that it may represent a "final common pathway" towards proliferation. We had, therefore, successfully aimed to inhibit this pathway through usage of rapamycin which potently inhibits mTOR  to not only prevent but also reverse vascular remodeling processes and right ventricular signs of pulmonary hypertension in mice held under hypoxic conditions.
Hypoxia is the main stimulus for the induction of pulmonary hypertension accompanying chronic ventilatory disorders such as chronic obstructive pulmonary disease and interstitial lung disease. While acute hypoxia causes selective pulmonary arteriolar vasoconstriction, chronic exposure to hypoxia results in morphological and functional changes in the pulmonary vascular bed [17–20]. Indeed, mTOR signaling seems to play a key role in hypoxia-triggered smooth muscle and endothelial cell proliferation in vitro . The requirement of PI3K, Akt, and mTOR for hypoxia-induced proliferation has also been demonstrated for pulmonary artery adventitial fibroblasts .
Although it is generally accepted that proliferation is an important contributor to hypoxia-induced vascular remodeling, only few data regarding the kinetics of the proliferative activity are available. Quinlan et al.  reported that the number of 5-bromo-2'-deoxyuridine-positive cells/vessel is about 50% higher in mice exposed to hypoxia for 4 or 6 days. After three weeks no differences in the proliferative index in the pulmonary vasculature of animals housed at normoxia or hypoxia were detectable. Our data confirm the finding of an only transient increase of proliferative activity within the pulmonary vasculature during hypoxia reaching a maximum within the first week. In our study this increase was sensitive to rapamycin treatment suggesting that inhibition of the early hypoxia-triggered cell cycle activity results in reduced chronic vascular remodeling. This way the drug may prevent further hypoxia-triggered proliferation and disease progression.
However, prevention of early proliferation does not explain rapamycin's effectiveness when given therapeutically after 3 weeks of hypoxia when proliferative activity within the pulmonary vasculature was determined even below that of normoxic mice. Rapamycin may inhibit the undetectable turnover the smooth muscle cells within the vessel wall are subjected to and, by this means, revert vascular muscularization when hypoxia had already resulted in pulmonary arterial remodeling. However, mTOR holds a critical role for activation of protein synthesis as well and, this way, seems to be involved in smooth muscle hypertrophy [21, 22]. Our data, indeed, indicate that rapamycin acts as a selective inhibitor of hypoxia-induced thickening of the muscle layer: Histologically, pulmonary vascular remodeling is characterized by de novo muscularization of small precapillary vessels and by smooth muscle cell hyperplasia and hypertrophy resulting in media thickening [14, 23]. With our assays we were able to quantify both processes: A classification based on the vessel caliber acted as an indicator for de novo muscularization of small arteries and the calculation of the ratio of "number of α-smooth muscle actin positive pixels within a vessel wall/minimal vascular diameter" was a criterion for the media thickening. Application of rapamycin prevented the hypoxia-induced increase in media thickening without affecting the degree of muscularization of lung vessels obtained from mice kept at normoxia. The relatively high proportion of vessels with calibers smaller than 20 μm diameter observed in mice kept at hypoxia was also detectable after rapamycin treatment. These results indicate that rapamycin had no effect on de novo muscularization of small arteries but acts as a selective inhibitor of hypoxia-induced thickening of the muscle layer. Presumably the de novo muscularization of precapillary vessels is caused by transdifferentiation of non-muscle cells and/or migration of smooth muscle cells from proximal to distal segments of the vascular system [14, 23]. Although rapamycin's effect on either processes have been demonstrated in growth factor-stimulated cells [24, 25], its effect on hypoxia-induced migration and/or transdifferentiation has not been investigated.
We propose that pulmonary vascular remodeling occurs in two steps: An initial phase of increased proliferative activity is followed by a second phase characterized by enhanced hypertrophy of vascular smooth muscle precursor cells leading to thickening of the media. Through its anti-proliferative and anti-hypertrophic effects rapamycin seems able to affect each phase.
An orally active derivative of rapamycin has previously been shown to attenuate monocrotaline-induced pulmonary hypertension in pneumonectomized rats . In this study, the drug was only effective when started simultaneously with the administration of monocrotaline. Late therapy did not affect pulmonary hypertension. The difference to our study may be due to the different models used. Monocrotaline has been proposed to cause perivascular inflammation and platelet activation, subsequently resulting in a proliferative response of the vascular media which is augmented by increased shear stress in the pulmonary bed after pneumoctomy . The difference may also lie in a transient inflammatory response after single monocrotaline treatment of rats. In this study, mice were exposed to hypoxia during the entire experimental period. Yet, this is the first study to show the effectiveness of rapamycin in preventing pulmonary hypertension induced by a pathophysiologic stimulus.
In our study, the extent of hypoxia-induced myocardial hypertrophy (RV/[LV+S]) was in good agreement with data published by other groups . Additionally, the diameter of individual cardiomyocytes was determined. Hypoxia induced a 20% increase in diameters of cardiomyocytes of the right ventricular wall while cardiomyocytes of the left ventricular wall were unaffected by changes in the oxygen supply. Hypoxia-induced hypertrophy of the right ventricle and of individual right ventricular cardiomyocytes was attenuated by treatment with rapamycin. In principle, hypertrophy of the right ventricular wall in response to hypoxia is caused by the ability to respond to increased mechanical stretch caused by pulmonary vasoconstriction and vascular remodeling. However, the capability of individual cardiomyocytes to sense changes in the oxygen supply and respond with hypertrophy has been suggested, too . In any case, recent data suggest that, in response to certain hypertrophic stimuli, signaling via mTOR is required for activation of protein synthesis and cardiac hypertrophy . Either mechanisms may have resulted in attenuation of right ventricular hypertrophy and cardiomyocyte diameter. A direct effect of the drug on cardiomyocyte size raises the possibility of detrimental effects on right ventricular function. However, when load-induced left ventricular hypertrophy was induced in mice, rapamycin treatment resulted in a decrease in chamber size and a normal systolic function of the left ventricle . However, disruption of coordinated cardiac hypertrophy has recently also been shown to contribute to the transition to heart failure as well .
In vascular medicine, local application of rapamycin through drug-coated stent placement is currently the favored invasive strategy to prevent restenosis . Systemic treatment with rapamycin is, furthermore, successfully used to prevent graft rejection and transplant vasculopathy in de novo heart transplant recipients . Rapamycin may represent a novel therapeutic strategy for pulmonary arterial hypertension in humans as well to delay further progression or even result in regression of pulmonary vascular remodeling.
The financial support of the Deutsche Forschungsgemeinschaft (Sonderforschungsbereich (SFB) 547, project C1 and Sonderforschungsbereich (SFB) 655, project A11) is gratefully acknowledged.
- Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351:1425–1436.View ArticlePubMedGoogle Scholar
- Rubin LJ: Primary pulmonary hypertension. N Engl J Med 1997, 336:111–117.View ArticlePubMedGoogle Scholar
- Wagenvoort CA: Vasoconstriction and medial hypertrophy in pulmonary hypertension. Circulation 1960, 22:535–546.View ArticlePubMedGoogle Scholar
- Kay JM, Kahana LM, Rihal C: Diffuse smooth muscle proliferation of the lungs with severe pulmonary hypertension. Hum Pathol 1996, 27:969–974.View ArticlePubMedGoogle Scholar
- Wohrley JD, Frid MG, Moiseeva EP, Orton EC, Belknap JK, Stenmark KR: Hypoxia selectively induces proliferation in a specific subpopulation of smooth muscle cells in the bovine neonatal pulmonary arterial media. J Clin Invest 1995, 96:273–281.View ArticlePubMedPubMed CentralGoogle Scholar
- Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F: Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115:2811–2821.View ArticlePubMedPubMed CentralGoogle Scholar
- Ghofrani HA, Seeger W, Grimminger F: Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005, 353:1412–1413.View ArticlePubMedGoogle Scholar
- Braun-Dullaeus RC, Mann MJ, Seay U, Zhang L, von Der Leyen HE, Morris RE, Dzau VJ: Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol 2001, 21:1152–1158.View ArticlePubMedGoogle Scholar
- Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315–1323.View ArticlePubMedGoogle Scholar
- Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, Togni M, Billinger M, Tuller D, Seiler C, Roffi M, Corti R, Sutsch G, Maier W, Luscher T, Hess OM, Egger M, Meier B: Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005, 353:653–662.View ArticlePubMedGoogle Scholar
- Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773–1780.View ArticlePubMedGoogle Scholar
- Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ: Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. Faseb J 2002, 16:771–780.View ArticlePubMedGoogle Scholar
- Gerasimovskaya EV, Tucker DA, Stenmark KR: Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast proliferation. J Appl Physiol 2005, 98:722–731.View ArticlePubMedGoogle Scholar
- Quinlan TR, Li D, Laubach VE, Shesely EG, Zhou N, Johns RA: eNOS-deficient mice show reduced pulmonary vascular proliferation and remodeling to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2000, 279:L641-L650.PubMedGoogle Scholar
- Goncharova EA, Ammit AJ, Irani C, Carroll RG, Eszterhas AJ, Panettieri RA, Krymskaya VP: PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2002, 283:L354-L363.View ArticlePubMedGoogle Scholar
- Barst RJ: PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005, 115:2691–2694.View ArticlePubMedPubMed CentralGoogle Scholar
- Ghofrani HA, Reichenberger F, Kohstall MG, Mrosek EH, Seeger T, Olschewski H, Seeger W, Grimminger F: Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 2004, 141:169–177.View ArticlePubMedGoogle Scholar
- Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR: Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001, 104:424–428.View ArticlePubMedGoogle Scholar
- Frisdal E, Gest V, Vieillard-Baron A, Levame M, Lepetit H, Eddahibi S, Lafuma C, Harf A, Adnot S, Dortho MP: Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J 2001, 18:838–845.View ArticlePubMedGoogle Scholar
- Weissmann N, Nollen M, Gerigk B, Ardeschir Ghofrani H, Schermuly RT, Gunther A, Quanz K, Fink L, Hanze J, Rose F, Seeger W, Grimminger F: Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. Am J Physiol Heart Circ Physiol 2003, 284:H931-H938.View ArticlePubMedGoogle Scholar
- Zhou L, Goldsmith AM, Bentley JK, Jia Y, Rodriguez ML, Abe MK, Fingar DC, Hershenson MB: 4E-binding protein phosphorylation and eukaryotic initiation factor-4E release are required for airway smooth muscle hypertrophy. Am J Respir Cell Mol Biol 2005, 33:195–202.View ArticlePubMedPubMed CentralGoogle Scholar
- Yamakawa T, Tanaka S, Kamei J, Kadonosono K, Okuda K: Phosphatidylinositol 3-kinase in angiotensin II-induced hypertrophy of vascular smooth muscle cells. Eur J Pharmacol 2003, 478:39–46.View ArticlePubMedGoogle Scholar
- Stenmark KR, Gerasimovskaya E, Nemenoff RA, Das M: Hypoxic activation of adventitial fibroblasts: role in vascular remodeling. Chest 2002, 122:326S-334S.View ArticlePubMedGoogle Scholar
- Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR: Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996, 98:2277–2283.View ArticlePubMedPubMed CentralGoogle Scholar
- Fukuda D, Sata M, Tanaka K, Nagai R: Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 2005, 111:926–931.View ArticlePubMedGoogle Scholar
- Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG, Kao PN: 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2001, 163:498–502.View ArticlePubMedGoogle Scholar
- Wilson DW, Segall HJ, Pan LC, Lame MW, Estep JE, Morin D: Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 1992, 22:307–325.View ArticlePubMedGoogle Scholar
- Minamino T, Christou H, Hsieh CM, Liu Y, Dhawan V, Abraham NG, Perrella MA, Mitsialis SA, Kourembanas S: Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci U S A 2001, 98:8798–8803.View ArticlePubMedPubMed CentralGoogle Scholar
- Ito H, Adachi S, Tamamori M, Fujisaki H, Tanaka M, Lin M, Akimoto H, Marumo F, Hiroe M: Mild hypoxia induces hypertrophy of cultured neonatal rat cardiomyocytes: a possible endogenous endothelin-1-mediated mechanism. J Mol Cell Cardiol 1996, 28:1271–1277.View ArticlePubMedGoogle Scholar
- Proud CG: Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 2004, 63:403–413.View ArticlePubMedGoogle Scholar
- Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ, Izumo S: Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003, 107:1664–1670.View ArticlePubMedGoogle Scholar
- Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH: A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989, 341:755–757.View ArticlePubMedGoogle Scholar
- Ong AT, Serruys PW: Technology Insight: an overview of research in drug-eluting stents. Nat Clin Pract Cardiovasc Med 2005, 2:647–658.View ArticlePubMedGoogle Scholar
- Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G, Macdonald P, Esmore D, Muller D, Faddy S: Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004, 110:2694–2700.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.